<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02827552</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00975-44</org_study_id>
    <nct_id>NCT02827552</nct_id>
  </id_info>
  <brief_title>Description of Individual Radiosensitivity With Molecular Biomarkers in a Pediatric Oncology Population</brief_title>
  <acronym>ARPEGE BioM</acronym>
  <official_title>Integrative Molecular Analysis of Individual Radiosensitivity Among a Population of Pediatric Patients Treated With Radiation in Eastern France.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore prospectively the distribution of individual radiosensitivity in&#xD;
      the pediatric population and to determine the predictive power of individual radiosensitivity&#xD;
      biomarkers from an immunofluorescence technique on primary dermal fibroblasts&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      900 children and adolescents benefit from radiation each year in France. The mean age at&#xD;
      diagnosis is 5 years; life expectancy for the 80% of them who could cure is long, and the&#xD;
      incidence of radiation-related acute and mainly late complications - not evaluated to date -&#xD;
      could exceed that of adults. Dysfunction of irradiated organs and growth disorders are&#xD;
      specific to the pediatric subpopulation. Individual radiosensitivity of children and&#xD;
      adolescents is unknown at this time, probably with large variability depending on the age&#xD;
      when considering the changes in metabolic functions throughout growth. These complications&#xD;
      are largely attributable to inter individual constitutional variations of cellular response&#xD;
      to DNA damage.&#xD;
&#xD;
      Subject to radiation-induced DNA damages such as double-strand breaks (DSB), cells reacts by&#xD;
      triggering a whole series of phosphorylation events coordinated within multi protein&#xD;
      complexes whose interplay is still misknown (DNA damage response i.e. DDR). Indirect&#xD;
      Immunofluorescence cell scanning has revolutionized radiation biology research by permitting&#xD;
      the detection of individual DSB in each cell nucleus in a dose range from 1 mGy to 10 Gy.&#xD;
      This technique has notably confirmed that yield of unrepaired DSB is correlated with cell RS.&#xD;
      From a broad spectrum of human radiosensitive skin fibroblast cell lines, the Inserm CRU 1052&#xD;
      team proposed a general model of DSB signaling and repair and a molecular assay to stratify&#xD;
      patients according to their individual RS.&#xD;
&#xD;
      ARPEGE biomarqueurs is a prospective multicenter study to prospectively evaluate with this&#xD;
      assay the RS of children and adolescents treated over a year in all pediatric oncology&#xD;
      departments of the Region Grand Est and set thresholds in this population. 150 children are&#xD;
      thus potentially includable in different centers. The assay will be performed on primary&#xD;
      fibroblasts cultured from a skin biopsy taken at diagnosis. The RS of patients will be&#xD;
      measured in blind. Confusion factors such as irradiated volume, skin phototype, previous&#xD;
      chemotherapy regimen, smoking, comorbities (diabetes, immunodeficiency, chronic inflammatory&#xD;
      disease ...) will be reported. In parallel the RT-acute toxicity will be reported according&#xD;
      to NCI-CTCAE v4.0 reference scale three months of the completion of RT then periodically&#xD;
      during 15 years.&#xD;
&#xD;
      Screening hypersensitive patients would be a major step forward in the management of cancers,&#xD;
      opening a view to personalized medicine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The liquidation of our industrial partner NEOLYS Diagnostics, directly involved in the&#xD;
    methodology of the study and a sub-optimal rate of inclusions which did not allow us to include&#xD;
    all patient within the allotted time.&#xD;
  </why_stopped>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Actual">February 7, 2020</completion_date>
  <primary_completion_date type="Actual">February 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>skin fibroblast radiosenstivity</measure>
    <time_frame>up to 5 months</time_frame>
    <description>residual double-strand breaks 24h after ex vivo radiation assessed with indirect immunofluorescence (gammaH2AX marker).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>early cutaneous, mucosal and hematological early radiation toxicity</measure>
    <time_frame>3 months</time_frame>
    <description>early radiation toxicity pattern assessed according to CTACAE v4.0 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pATM nucleoshuttling</measure>
    <time_frame>up to 5 months</time_frame>
    <description>pATM foci counted 10 minutes and 1 hour after ex vivo radiation assessed with indirect immunofluorescence (pATM marker).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean micronuclei number</measure>
    <time_frame>up to 5 months</time_frame>
    <description>micronuclei counted 24 hours after ex vivo radiation assessed with indirect immunofluorescence (DAPI marker).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late radiation toxicity</measure>
    <time_frame>15 years</time_frame>
    <description>deterministic tissue effects as well as secondary malignancies occurring in radiation field more than 3 months and up to 15 years after RT, using CTCAE v4.0 scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cancer-related Problem/Condition</condition>
  <arm_group>
    <arm_group_label>ARPEGE BioM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>N/A (not a randomized study)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>skin biopsy</intervention_name>
    <description>skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient</description>
    <arm_group_label>ARPEGE BioM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children &lt; 18 years old&#xD;
&#xD;
          -  Patient with an indication of radiotherapy&#xD;
&#xD;
          -  Patient must be affiliated to a social security system&#xD;
&#xD;
          -  Patient under parental autority&#xD;
&#xD;
          -  Ability to provide an informed written consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for skin biopsy&#xD;
&#xD;
          -  Contraindications for radiotherapy&#xD;
&#xD;
          -  Referred to palliative radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy in the same area&#xD;
&#xD;
          -  Indication of hypofractionated radiotherapy&#xD;
&#xD;
          -  Patient monitoring impossible&#xD;
&#xD;
          -  Patients deprived of liberty or under supervision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VOGIN GUILLAUME, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BERNIER CHASTAGNER VALERIE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georges-François-Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51 100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67 098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54 500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric oncology</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>radiosensitivity</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

